Merck stock holds gains as Keytruda drives double digit revenue growth

Merck stock reflects a business increasingly shaped by oncology leader Keytruda, with double digit revenue growth and rising margins underpinned by the companys latest quarterly figures.

Merck & Co., Inc. (ISIN US58933Y1055) is one of the largest US pharmaceutical groups, and Merck stock increasingly mirrors the companys shift toward high growth oncology therapies led by its immunotherapy Keytruda. In its most recent reported quarter, Merck generated total revenue of around $15 billion, with double digit year on year growth supported by expanding cancer and vaccines franchises. The latest figures showed higher operating profitability as well, with margin improvements helping the group to fund research and shareholder returns.

Revenue up double digits

According to Mercks most recently available quarterly results, total revenue for the period was approximately $15 billion, up about 9% compared with the same quarter a year earlier. That year on year increase illustrates how the companys portfolio is growing even as some legacy products face competitive and patent headwinds. For investors, the revenue trend matters because it provides a quantitative signal that Merck is offsetting pressures from loss of exclusivity with growth in oncology and vaccines.

Within that total, oncology therapies contributed a rising share. Sales of Keytruda, Mercks flagship programmed death receptor-1 (PD-1) inhibitor used in a broad range of cancers, reached around $6 billion in the latest quarter, compared with roughly $5 billion in the prior year period. That implies growth of about 20% year on year for Keytruda alone, a pace that significantly exceeds the overall group revenue increase and underlines its role as Mercks single most important product.

Keytruda and vaccines underpin margin

Mercks vaccine franchise also contributed meaningfully to the top line. In the same reporting period, vaccines revenue was about $3 billion, compared with roughly $2.5 billion a year earlier, implying growth of around 20% year on year. Key contributors include human papillomavirus vaccine Gardasil, which has benefited from broader international uptake and ongoing public health immunization efforts. The combination of oncology and vaccines has thus become a central pillar in Mercks strategy to deliver sustainable growth.

Beyond revenue, Merck reported non-GAAP earnings per share of about $2.00 in the quarter, versus roughly $1.70 a year earlier, an increase of close to 18%. This EPS expansion reflects both higher sales and operating leverage as the company scales its oncology and vaccine platforms. For shareholders, the earnings progression gives context to Merck stock valuations because it shows that profit growth is tracking or exceeding revenue growth, rather than lagging behind.

Merck also highlighted continued investment in research and development. R&D spending in the recent quarter was approximately $3 billion, modestly higher than the prior year period. While that represents a significant cost, it is central to maintaining and expanding indications for Keytruda and advancing pipeline candidates in oncology, cardiometabolic disease, and immunology. The balance between R&D intensity and margin expansion is a key analytical focus for many market participants when they assess Merck stock.

Guidance supports long term growth

In its latest full year outlook, Merck guided for annual revenue in a range around $60 billion, implying mid single digit to high single digit growth compared with the prior year. The company also indicated that oncology and vaccines would remain the primary growth drivers, while animal health and hospital acute care medicines provide additional diversification. Compared with the previous year, when revenue was closer to $58 billion, the guided range suggests incremental progress rather than a plateau.

On the earnings side, Merck projected non-GAAP EPS for the full year at roughly $8.50 at the midpoint of guidance, versus about $8.00 in the previous fiscal year. That roughly 6% increase indicates that management expects margin support from product mix and operational efficiencies, even as it continues to absorb higher R&D and manufacturing costs. The guidance therefore anchors expectations for Merck stock valuations and offers a quantitative benchmark against which future quarters will be judged.

The company also continues to return capital through dividends. Mercks annual dividend amounts to roughly $3.00 per share, based on the most recently declared rate, compared with about $2.60 per share two years earlier. That step up in the payout reflects confidence in cash generation and a desire to maintain the companys appeal to income oriented investors, while still keeping headroom for reinvestment into the pipeline.

Keytruda shapes Mercks profile

Keytruda has become the defining product for Merck, with a broad label that covers multiple tumor types and both first line and subsequent line therapy settings. In the latest reported year, Keytruda generated annual revenue of about $25 billion, compared with roughly $20 billion the year before. That 25% year on year growth at the product level is a critical quantitative marker for Mercks strategy, as it shows that oncology is increasingly central to the group.

The breadth of Keytrudas indication base, spanning lung, melanoma, renal cell carcinoma, head and neck cancer, and others, provides a platform for continued expansion. Ongoing clinical trials aim to move the medicine into earlier disease stages and combinations with other agents, which could further support revenue over time. For Merck stock, the durability and growth potential of Keytruda sales are often central to analysts valuation frameworks.

At the same time, concentration risk is an important consideration. With Keytruda representing a large share of total revenue, future patent expiry and competitive dynamics are closely watched. Merck is therefore investing heavily in next generation oncology assets and in lifecycle management strategies that could extend Keytrudas value. The companys R&D spend of around $3 billion per quarter illustrates its commitment to mitigating the eventual impact of loss of exclusivity.

Vaccines and other franchises

Gardasil, Mercks human papillomavirus vaccine, is another major growth driver. In the most recent full year, Gardasil generated revenue of roughly $8 billion, up from about $6 billion a year earlier, implying around 33% growth. That expansion reflects strong demand in markets such as China and continued programs aimed at preventing HPV related cancers globally. For Merck stock, the vaccine franchise adds a distinct defensive and public health oriented element to the growth story.

Mercks animal health segment also contributes steady revenue. Annual animal health sales are around $6 billion, with low to mid single digit growth compared with the prior year. While smaller than oncology and vaccines, this business provides diversification across species and geographies and tends to exhibit relatively stable demand patterns, which can help smooth volatility in the pharmaceutical segment.

Other human health products, including hospital acute care medicines and cardiometabolic therapies, add to Mercks portfolio breadth. Some of these segments are more mature and grow slowly, but they provide cash flow that can be redirected into high growth areas. The mix of high growth oncology and vaccines with steadier mature products is a key element of the companys overall risk profile from an equity perspective.

Merck stock and valuation context

From a market perspective, Merck stock is generally valued as a large cap defensive growth name within the pharmaceutical sector. With annual revenue in the region of $60 billion and non-GAAP EPS guidance around $8.50 at the midpoint, the companys earnings base is substantial. Its dividend of about $3.00 per share and ongoing share repurchases contribute to total shareholder return and are often factored into yield oriented strategies.

Mercks exposure to oncology and vaccines means its fortunes can be somewhat differentiated from peers more heavily weighted toward primary care or rare disease. For example, compared with another big US pharmaceutical company whose revenue growth might be low single digit due to patent expiries, Mercks double digit product level growth in Keytruda and Gardasil provides a contrast that helps explain relative market performance over recent years.

At the same time, Merck stock can be sensitive to clinical trial outcomes and regulatory decisions. Positive data in new indications for Keytruda or successful late stage trials for pipeline assets may support higher earnings expectations, while setbacks can lead to downward revisions. Investors therefore often follow not only financial metrics but also detailed medical and regulatory developments when assessing Merck.

Representative product focus

Keytruda is the most representative product for understanding Mercks current trajectory. Approved initially for melanoma and now used across a wide range of solid tumors, it works by blocking the PD-1 pathway, enabling the immune system to recognize and attack cancer cells more effectively. The medicine has become a standard of care in several indications, and its broad label supports the multibillion dollar annual revenue levels Merck now reports.

From a business perspective, Keytruda exemplifies Mercks strategy of investing in high science, high impact therapies that can deliver strong clinical benefit and significant commercial returns. The product also demonstrates how regulatory approvals across geographies, real world data, and ongoing clinical development can sustain long term growth in a single asset. As Merck continues to advance new oncology agents, the companys experience with Keytruda provides a framework for future launches.

Merck stock trading snapshot

Merck stock is listed on the New York Stock Exchange and trades under the ticker MRK. As a large constituent of major US equity indices, the shares are widely held by institutional and retail investors alike. For many, the combination of growth in oncology and vaccines, a meaningful dividend, and exposure to a diversified pharmaceutical portfolio defines the investment case, even as they weigh pipeline risks and future competition.

Merck stock key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: NYSE: MRK
• Trading venue: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500